ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
The tumor suppressor protein p150(Sal2) in carcinogenesis.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- SALL Proteins; Common and Antagonistic Roles in Cancer.Cancers · 2021Review
- CRISPR-mediated promoter de/methylation technologies for gene regulation.Archives of pharmacal research · 2020Review
- Transcriptomic analysis reveals that BMP4 sensitizes glioblastoma tumor-initiating cells to mechanical cues.Matrix biology : journal of the International Society for Matrix Biology · 2020Article
- mRNA and methylation profiling of radioresistant esophageal cancer cells: the involvement of Sall2 in acquired aggressive phenotypes.Journal of Cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transcription factor p150(Sal2), the product of the SALL2 gene, was first identified as a binding target of the oncogenic mouse polyomavirus T antigen. However, mouse polyomavirus is not the only oncogenic virus that targets p150(Sal2); the human papillomavirus E6 protein also targets this cellular protein in order to overcome p150(Sal2)-mediated growth arrest. Studies have demonstrated that p150(Sal2) recognizes GC-rich regions of the promoter and transcriptionally induces p21(Cip1/Waf1) and BAX in human ovarian epithelial cancer cells, resulting in cell growth arrest and apoptosis. Although the p150(Sal2) protein is strongly expressed in surface epithelial cells of the ovary, immunostaining experiments showed that expression of p150(Sal2) was lost in 90 % of 210 human ovarian carcinomas, supporting an important tumor suppressive role for p150(Sal2) in the human ovary. Mechanisms of silencing SALL2 in OVCA cell lines and primary tumors and possible therapeutic approaches for ovarian carcinoma are discussed in this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.